Broadening of intellectual property portfolio for these two NCEs clearly defines development pathway for the next generation of psychedelic medicines to treat addiction TORONTO, CANADA, 28 June 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the filing…


Previous articleMindMed Included in FTSE Russell 3000® Index
Next articleLobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board